Successful response to camrelizumab in metastatic bladder cancer: A case report
Chen Xie1, Xia Yuan1, Shu-Hui Chen1
1Department of Radiotherapy, Jiangxi Provincial Tumour Hospital, Nanchang 330029, Jiangxi Province, China.
Background:
There has been no report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive programmed death-ligand 1 (PD-L1) expression and high tumor mutational burden (TMB). More effective predictors of bladder cancer immunotherapy have yet to be explored, and the combination of multiple factors may be more predictive than a single factor.
Case Summary:
We report the case of a 74-year-old male patient with recurrent metastatic bladder cancer, which demonstrated positive PD-L1 expression and high TMB. The immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin. The patient achieved a partial response with a progression-free survival of 11 mo.
Conclusion:
This is the first report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive PD-L1 expression and high TMB.
Insights
This study introduces camrelizumab combined with chemotherapy for advanced bladder cancer patients with high tumor mutational burden (TMB) and positive programmed death-ligand 1 (PD-L1) expression. The combination showed a partial response and 11-month progression-free survival.
Area of Science:
- Oncology
- Immunotherapy
- Genitourinary Cancers
Background:
- Advanced bladder cancer treatment remains challenging, necessitating novel therapeutic strategies.
- Predictive biomarkers for immunotherapy response, such as programmed death-ligand 1 (PD-L1) expression and tumor mutational burden (TMB), are crucial.
- The combination of immune checkpoint inhibitors with chemotherapy for advanced bladder cancer with specific biomarker profiles has not been previously reported.
Observation:
- A 74-year-old male patient with recurrent metastatic bladder cancer presented with positive PD-L1 expression and high TMB.
- The patient received camrelizumab, an immune checkpoint inhibitor, in combination with gemcitabine and cisplatin chemotherapy.
Findings:
- The combination therapy resulted in a partial response.
- The patient achieved a progression-free survival of 11 months.
Implications:
- This case report is the first to document the use of camrelizumab with chemotherapy in advanced bladder cancer patients exhibiting both positive PD-L1 expression and high TMB.
- This combination therapy demonstrates potential efficacy and warrants further investigation in clinical trials.
- Identifying optimal predictive biomarkers for immunotherapy response in bladder cancer is essential for personalized treatment approaches.
